SLC5A2 and kidney disorder: It is, however, concerning that people with prevalent CVD had a lower probability of receiving SGLT2 inhibitors versus those without, since trials comparing SGLT2 inhibitors versus placebo have shown substantial improvements in diabetic‐related outcomes among those with atherosclerotic CVD, heart failure, and kidney disease.38, 42, 43